search
Back to results

Intraoperative Gamma Camera for Breast Cancer Surgery

Primary Purpose

Breast Cancer, Ductal Carcinoma in Situ

Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
SLN procedure (CarolIReS camera)
Sponsored by
University Hospital, Strasbourg, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer focused on measuring breast cancer, CarolIReS, intraoperative gamma camera, lymphoscintigraphy, sentinel lymph node, Hundred and ten patients with infiltrative breast cancer or ductal carcinoma in situ (DCIS), diagnosed preoperatively by core biopsy or cytology.

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient major at the time of breast surgery.
  • Patient affiliated with a social security.
  • Consent dated and signed by the investigator and the subject.
  • Subject having been informed of the sentinel lymph node procedure during the visit prior to breast surgery.
  • Patient having a unifocal infiltrative breast cancer (less than 2 cm) diagnosed preoperatively by core biopsy or cytology.
  • Patient having a ductal carcinoma in situ (DCIS), diagnosed preoperatively by core biopsy or cytology.

Exclusion Criteria:

  • Refusal of the patient to be included in the study.
  • Pregnant patient or during breastfeeding.
  • None of the patients will have undergone chemotherapy, locoregional radiotherapy or prevalent axillary lymph node.
  • Diagnosed safeguarding justice and trust.
  • Patient with a psychiatric disorder makes it impossible for the collection of informed consent-patient with tumors greater than 2 cm or multifocal.
  • Prevalent axillary lymph node.

Sites / Locations

  • CHRU, Hôpital Civil ,Service de Gynécologie-obstétrique

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

I

II

Arm Description

For the first 10 patients, only a pre-operative procedure will be performed.

The last 100 patients will receive the complete procedure.

Outcomes

Primary Outcome Measures

Proportion of subjects for which the gamma camera can detect sentinel lymph nodes (SLN) not identified by other technic.

Secondary Outcome Measures

Proportion of subjects with at least one additional sentinel lymph nodes (SLN) detected by preoperative pictures with gamma camera.
Proportion of subjects with at least one additional sentinel lymph nodes (SLN) detected by the pictures with gamma camera to intervene.

Full Information

First Posted
September 22, 2008
Last Updated
September 29, 2015
Sponsor
University Hospital, Strasbourg, France
Collaborators
Institut Pluridisciplinaire Hubert Curien. UMR 7178 - CNRS/IN2P3, ULP. F-67037 Strasbourg, National Cancer Institute, France
search

1. Study Identification

Unique Protocol Identification Number
NCT00757302
Brief Title
Intraoperative Gamma Camera for Breast Cancer Surgery
Official Title
Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
September 2015
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Strasbourg, France
Collaborators
Institut Pluridisciplinaire Hubert Curien. UMR 7178 - CNRS/IN2P3, ULP. F-67037 Strasbourg, National Cancer Institute, France

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Aim: This study aims at evaluating the performances of an intraoperative gamma camera (field of view 10X10 cm), named CarolIReS, to detect axillary drainage and to assess the removal of sentinel lymph nodes (SLN) in breast surgery. Patients and Methods: SLN biopsy will be performed on 110 patients and the CarolIReS camera will be used preoperatively to localize SLNs. During surgery, individual removal of SLNs will be performed using a gamma probe named CarolIReS and their activity will be measured with a gamma ray counter. At the end of surgery, the CarolIReS camera will be used again to check the quality of surgery which will be followed by a surgical excision in case of remaining SLNs. Objectives: The main objective of this study is to evaluate the performances of the CarolIReS camera in assessing the axillary drainage of breast tumors and the surgical removal of SLNs. In addition, the possible correlation between the activity, the size, and the metastatic involvement of the SLNs will also be studied.Study hypothesis: Intraoperative cameras could be used to improve the efficiency of the SLN procedure
Detailed Description
Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²). During surgery, the search for radioactive nodes will be performed using the CarolIReS probe. In order to evaluate the CarolIReS camera sensitivity, the activity of the removed SLNs will be measured immediately after their resection by a gamma ray counter and they will then be submitted to pathological analysis with frozen section. Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²). During surgery, the search for radioactive nodes will be performed using the CarolIReS probe. In order to evaluate the CarolIReS camera sensitivity, the activity of the removed SLNs will be measured immediately after their resection by a gamma ray counter and they will then be submitted to pathological analysis with frozen section. After SLN removal and during the pathological analysis, the axillary area will once again be checked using the CarolIReS camera (followed by a further surgical excision in the case of remaining SLNs). When the pathological analysis will diagnose a metastatic SLN, complete axillary lymph node dissection (ALND) will immediately be performed. In the case of negative SLN, serial sections and detection of cytokeratine (AE1/AE3; Dako, Zymed, CA, USA) will be performed during standard pathological analysis. Macrometastases will be defined as clusters of cancer cells ≥2 mm, micrometastases as clusters of cancer cells ≥0.2 mm and <2 mm, and isolated cancer cells as clusters of cancer cells <0.2 mm. ALND will be performed in cases of macro- or micrometastases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Ductal Carcinoma in Situ
Keywords
breast cancer, CarolIReS, intraoperative gamma camera, lymphoscintigraphy, sentinel lymph node, Hundred and ten patients with infiltrative breast cancer or ductal carcinoma in situ (DCIS), diagnosed preoperatively by core biopsy or cytology.

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
110 (Actual)

8. Arms, Groups, and Interventions

Arm Title
I
Arm Type
Experimental
Arm Description
For the first 10 patients, only a pre-operative procedure will be performed.
Arm Title
II
Arm Type
Experimental
Arm Description
The last 100 patients will receive the complete procedure.
Intervention Type
Device
Intervention Name(s)
SLN procedure (CarolIReS camera)
Other Intervention Name(s)
gamma camera carolires in detection on sentinel lymph node
Intervention Description
Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²). Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).
Primary Outcome Measure Information:
Title
Proportion of subjects for which the gamma camera can detect sentinel lymph nodes (SLN) not identified by other technic.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Proportion of subjects with at least one additional sentinel lymph nodes (SLN) detected by preoperative pictures with gamma camera.
Time Frame
1 year
Title
Proportion of subjects with at least one additional sentinel lymph nodes (SLN) detected by the pictures with gamma camera to intervene.
Time Frame
1 year

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient major at the time of breast surgery. Patient affiliated with a social security. Consent dated and signed by the investigator and the subject. Subject having been informed of the sentinel lymph node procedure during the visit prior to breast surgery. Patient having a unifocal infiltrative breast cancer (less than 2 cm) diagnosed preoperatively by core biopsy or cytology. Patient having a ductal carcinoma in situ (DCIS), diagnosed preoperatively by core biopsy or cytology. Exclusion Criteria: Refusal of the patient to be included in the study. Pregnant patient or during breastfeeding. None of the patients will have undergone chemotherapy, locoregional radiotherapy or prevalent axillary lymph node. Diagnosed safeguarding justice and trust. Patient with a psychiatric disorder makes it impossible for the collection of informed consent-patient with tumors greater than 2 cm or multifocal. Prevalent axillary lymph node.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
MATHELIN Carole, MD
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHRU, Hôpital Civil ,Service de Gynécologie-obstétrique
City
Strasbourg
ZIP/Postal Code
67091
Country
France

12. IPD Sharing Statement

Learn more about this trial

Intraoperative Gamma Camera for Breast Cancer Surgery

We'll reach out to this number within 24 hrs